Analyst Research Report Snapshot


Glenmark Pharmaceuticals Ltd. | Q2FY14 First Cut Analysis




IndiaNivesh Securities Pvt Ltd


01 Nov 2013





Companies referenced:


Available for Immediate Download

Glenmark Pharmaceuticals Ltd. | Q2FY14 First Cut Analysis Inline with estimates | Valuations: At CMP of Rs 562, the stock is trading at P/E multiple of 19.9x & 15.9x of FY14E & FY15E earnings estimates respectively. We continue to have BUY rating on the stock with the target price of Rs 636. We intend to come out with detailed analysis after attending con call scheduled for today (1st November 2013).

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.